With the exception of prolonged progression-free survival (but not overall survival) achieved with bevacizumab—a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)—no pharmacological intervention has been definitively shown to alter the course of GBM [126]. This evidence concerns the gene VEGFA and glioblastoma.